Get notified when OTLK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company and its auditor both state substantial doubt about its ability to continue as a going concern, which may persist after the offering.
- Class Action Lawsuit (new) — The company is a defendant in a class action lawsuit and a shareholder derivative action, which could result in significant costs and management distraction.
- Atlas Sciences Note Terms (new) — The $19.8 million Atlas Sciences note carries a 7.5% exit fee and quarterly redemption rights, creating significant cash obligations.
Outlook Therapeutics files to sell stock and warrants; terms blank, net proceeds to fund LYTENAVA launch
Filed August 12, 2026 · ~1 min read
Key Changes
-
high
Outlook Therapeutics is offering common stock and purchase warrants, but the number of shares, warrants, and price are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
high
Net proceeds will fund the U.S. commercial launch of LYTENAVA and general corporate purposes, with amounts unspecified.
Use of Proceeds verify on EDGAR → -
high
The company had a net tangible book deficit of $29.0 million ($0.28 per share) as of March 31, 2026; pro forma net tangible book value was $8.2 million ($0.04 per share), so new investors will experience immediate dilution.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade OTLK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify